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often below those required to control gross disease. This 
study was done to explore the incidence of brachial plexus 
injury following radical (chemo) radiotherapy in the IMRT 
era. 
 
Material and Methods: Patients with head and neck cancer 
that had completed IMRT to unilateral or bilateral neck with 
a minimum of 2 years of follow up were identified from a 
prospective database. All patients underwent clinical review 
as per local protocol which was commonly 6 weekly. The 
brachial plexus was contoured based on RTOG Atlas. 
Maximum dose (Dmax) to brachial plexus was recorded from 
DVH. All doses were converted to BED using an α/β ratio of 2. 
A review of electronic records was performed to determine 
brachial plexus toxicity using CTCAE v 3.0. 
 
Results: Seventy five patients met the inclusion criteria. Ten 
patients were excluded due to insufficient dose metric data. 
Of sixty five patients analysed, 37 patients were treated for 
oropharyngeal, 2 for nasopharyngeal, 6 for Hypopharyngeal, 9 
for Larynx, 8 for oral cavity cancers and 3 for unknown 
primary site. Forty five patients had concurrent 
chemotherapy (31 cisplatin, 8 carboplatin and 6 cetuximab). 
Brachial plexus dosimetry is given in table 1. Maximum point 
BED to brachial plexus reached 149.5Gy2 (41.3-149.5). There 
were no reported symptoms of brachial plexopathy during 
this period. 
 
Conclusion: It is often necessary to accept higher than 
conventional maximum point doses to the brachial plexus to 
ensure adequate PTV coverage for head and neck cancers. 
Although longer term follow-up is required ideally with nerve 
conduction studies, such an approach of exceeding 
conventional limits appears to be acceptable. Further data 
will be presented for patients exceeding conventional 
constraints. 
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Purpose or Objective: To present long-term results on 
disease control and late toxicity in both primary and post-
operative re-irradiation in the head and neck region. 
 
Material and Methods: Retrospective single center analysis 
of 137 patients re-irradiated between 1986 and 2013 for a 
recurrent or second primary malignancy. Inclusion criteria 
were a prescribed dose of at least 45 Gy in first treatment 
and re-treatment and histological proof of disease. Exclusion 
criteria were age under 18 years, the presence of metastatic 
disease and the use of brachytherapy. Endpoints were 
locoregional control (LRC), disease-free survival (DFS), event-
free survival (EFS), overall survival (OS) and grade ≥3 late 
complications according to EORTC/RTOG criteria. EFS 
includes both disease recurrence and late treatment 
complication as an event.  
As 3D-dose distribution data was not available for all 
patients, a descriptive approach was used to determine the 
highest cumulative dose in radiation overlap and organs at 
risk (spinal cord, larynx, mandible and optical nerve).  
 
Results: Patient and tumor characteristics are presented in 
table 1. 
 
  
The median re-irradiation and cumulative radiation dose 
were 60 Gy (range 45-70) and 126 Gy (range 68-138) 
respectively. Two- and five-year LRC were 52% and 40%, two- 
and five-year DFS were 38% and 28% respectively (figure 1). 
There were 17 observations of serious late toxicity in 11 
patients (actuarial 26% at 5 years): chondronecrosis (n=1), 
osteoradionecrosis (n=8), soft tissue necrosis (n=3), arterial 
blowout (n=3), and stricture/fistula (n=2). Three cases of 
treatment-related death were reported. Multivariate analysis 
revealed IMRT as re-irradiation technique to be protective of 
late complications (HR, 0.10; 95% CI, 0.01-0.96). The five-
year actuarial EFS was 18%.  
 
 
One-hundred-and-seven patients (78%) were re-irradiated 
post-operatively and had a better LRC in comparison to re-
irradiation alone (actuarial 5-yr 46% vs 16%, p<0.05). Of 
patients re-irradiated alone without surgery, patients re-
irradiated for a second primary tumor had significant better 
LRC-rates in comparison with patients re-irradiated for 
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recurring tumors (actuarial 5-yr 44% vs 0% p<0.05). Four cases 
of mandibular osteoradionecrosis were seen (cumulative dose 
range 106-128 Gy). Fifty-three patients received a cumulative 
dose of 100 Gy or higher. The actuarial 5-year mandibular 
necrosis rate in this group was 26%. 
 
Conclusion: Re-irradiation in the head and neck region for a 
recurrent or second primary malignancy is associated with 
LRC-rates of 40%. Results in patients re-irradiated post-
operatively are more favorable. Approximately one in six 
patients survived at 5 years without a recurrence or a serious 
late toxicity. The most important limitation for re-irradiation 
is late toxicity, which can be limited with current IMRT 
techniques. 
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Purpose or Objective: We have previously developed a 
mixture NTCP model for radiation-induced HT in a cohort of 
patients with head and neck cancer treated at the 
Department of Oncology, Odense University Hospital (OUH), 
Denmark. The model was validated in an independent cohort 
of patients treated at the Department of Oncology, Aarhus 
University Hospital (AUH). One plasma TSH assessment after 
RT was used in the external validation cohort and the latency 
time function of the model could therefore not be validated. 
The aim of this study was to validate the latency function by 
including repeated thyrotropin (TSH) measurements and a 
longer follow-up in the validation cohort. 
 
Material and Methods: Initially, 198 patients were included 
in the validation cohort. From July 2012- October 2014 
further TSH measurements were collected in 171/198 
patients, increasing the median follow-up from 22 to 38 
months after RT. The endpoint, HT, was defined as TSH>4.0 
mU/l. Data were analyzed using a mixture model taking both 
thyroid volume (Vthyroid) and dose (Dmean) into account. 
From the repeated blood samples, latency was estimated and 
both the latency time function and NTCP models in AUH were 
compared to OUH. Validation was performed using a 
calibration plot of binned groups of patients showing the 
clinically observed outcome in the validation cohort 
compared with the predicted outcome from the original NTCP 
model. 
 
Results: With the additional follow-up, 40 patients (20%) 
developed HT (19 after one TSH assessment). Dmean and 
Vthyroid were still significant risk factors for HT, OR=1.11 
(1.06-1.19) and OR=0.85 (0.74-0.93), respectively. The 
cumulative events showed that 94% (59-100%) of the events 
would develop within the first five years after RT in the 
validation cohort, in line with the original cohort’s 97% (85-
100%). Mean thyroid volumes were 17.4 (OUH) and 17.3 (AUH) 
cm3, and tolerance estimates around this level showed TD25 
=38 Gy and 34 Gy, respectively, at 15 cm3 and 48 Gy and 
42Gy, respectively, at 20 cm3. The calibration plot (Fig. 1) 
showed good agreement between the observed incidences of 
HT in the validation group versus the expected probability of 
HT from the original model. Thus, the NTCP model has 
external validity in the cohort with multiple blood tests. 
 
 
 
Conclusion: Increasing thyroid dose and a decreasing thyroid 
volume were confirmed as significant risk factors for 
radiation-induced HT, which likely develops within the first 
five years after RT. The calibration plot shows that the 
original NTCP model has external validity, supporting that 
risk estimates from the NTCP model may be used to support 
clinical treatment planning decisions relating to development 
of hypothyroidism after RT to the neck area.  
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Purpose or Objective: Head and neck cancer (HNC) is the 
sixth most common type of cancer in Europe. Its early 
symptoms are usually non-specific and easy to miss, which in 
many patients lead to late presentation and diagnosis. Main 
risk factors of HNC include alcohol consumption and smoking. 
Both of them are usually present in young people, thus health 
education in this group is of great importance. The aim of the 
study was to assess the level of HNC awareness among young 
population in Poland. 
 
Material and Methods: An anonymous online survey about 
HNC was conducted among 1903 people in the age of 18-35 
years, mainly students of high schools and universities. The 
closed-ended questions concerned HNC risk factors, 
symptoms and prognosis. Participation in the study was 
voluntary. 
 
Results: 85% of respondents had heard about HNC. The main 
source of information was the Internet (57%). Seventy-eight 
percent of participants associated smoking with HNC 
development, but alcohol consumption was mentioned by less 
than a half, and human papillomavirus (HPV) infection by 
approximately ⅓ of them. The main risk factors mentioned by 
students of non-medical schools included smoking (66%), 
stress (33%), and excessive sunbathing (32%). One fourth of 
the respondents (38% when excluding medical students) were 
unaware of any HNC early symptoms. The symptoms 
mentioned most often included chronic hoarseness (55%), 
lump in the neck (52%), and chronic sore throat (51%). Over 
¾ of medical students and half of other respondents were 
aware that early diagnosis is associated with a great chance 
